

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.**

Substitute for form 1449A/PTO				Complete If Known	
				Application Number	10/662,820
				Filing Date	September 16, 2003
				First Named Inventor	Koike et al.
				Art Unit	To Be Assigned 1614
				Examiner Name	To Be Assigned HENRY
				Attorney Docket Number	1089.04100017JUM
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(Use as many sheets as necessary)</small>					
Sheet <b>MARK OF MAY 01 2004 JC8</b>	1	of	2		

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	11/12/04
--------------------	---	-----------------	----------


**\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Identify copy of this document by date and attorney or agent's name and docket number (national). See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801-04.**

(form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 501.04.  
\*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English-Japanese Translation is attached.

here if English language translation is attached.  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
				Application Number	10/662,820
				Filing Date	September 16, 2003
				First Named Inventor	Koike et al.
				Art Unit	To Be Assigned 1414
				Examiner Name	To Be Assigned <i>HEN</i>
Sheet 1 of 1	2	Of	2	Attorney Docket Number	
1089.0410001/TUM					



## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
<i>JH</i>	AA2	"Comparison of Antitumor Activity of Vitamins K <sub>1</sub> , K <sub>2</sub> and K <sub>3</sub> on Human Tumor Cells By Two (MTT and SRB) Cell Viability Assays," Felicia Y. - H. Wu et al., Life Sciences, Vol. 52 pp. 1797-1804, Pergamon Press 1993.	
	AB2	"Changes of Plasma Des-y-Carboxy Prothrombin Levels In Patients With Hepatocellular Carcinoma In Response to Vitamin K," Midori Furukawa et al., Cancer, Vol. 69, Number 1, pp. 31-38, J.B. Lippincott Company, Philadelphia, January 1, 1992.	
	AC2	"DES-y-Carboxy Prothrombin As A Useful Predisposing Factor for the Development of Portal Venous Invasion in Patients with Hepatocellular Carcinoma," Yukihiro Koike et al., Cancer, Vol. 91, Number 3, pp. 561-569, John Wiley & Sons, Inc., February 1, 2001.	
	AD2	"The Growth Inhibitory Effects of Vitamins K and Their Actions On Gene Expression," Ziqiu Wang et al., Hepatology, Vol. 22, pp. 876-882, September 1995.	
	AE2	O'Neil, J.M. et al., The Merck Index Thirteenth Edition, Merck & Co., Inc., 2001 pg. I787, Item 10082 on Vitamin K.	
	AF2	Randomized Prospective Study of Prevention from Tumor Invasion Into Portal Vein In 120 Patients with Hepatocellular Carcinoma by Vitamin K Administration, <a href="http://ddw02.agora.com/planner/displayabstract.asp?presentationid=31">http://ddw02.agora.com/planner/displayabstract.asp?presentationid=31</a> , July 8, 2002.	
	AG2	38 <sup>th</sup> Annual Meeting of Liver Cancer Study Group of Japan, Item 110, p. 135, Inhibitory Effect of Vitamin K Injection Against the Recurrence of Hepatocellular Carcinoma, published on May 13, 2002	✓
	AH2	Japanese Journal of Gastroenterology, Vol. 99 Supplement, March 20, 2002, Item 308, A Clinical Study of the Effects of Vitamin K in Inhibiting Recurrence of Hepatocellular Carcinoma	✓
<i>WJ</i>	AI2	ACTA Hepatologica Japonica, Vol. 43 Supplement (1) 2002, May 20, 2003, Item O-98, A Randomized Prospective Controlled Study by Vitamin K-II Injection for the Purpose of Preventing Portal Venous Invasion (PVI)	✓

Examiner Signature

*RdJ/HZ*

Date Considered

11/12/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.